Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Keep in a tightly closed vial, store in refrigerator
Synonyms
5-fluoro-3-(2,3,4,5,6-pentadeuteriophenyl)-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Idelalisib-d5 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Idelalisib-d5 usage and description
Idelalisib D5 is a deuterium-labeled form of idelalisib, a phosphoinositide 3-kinase (PI3K) inhibitor that is used in the treatment of certain types of cancers. It is commonly used in the treatment of chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL).
Idelalisib D5 works by inhibiting the PI3K delta isoform, which is responsible for the growth and survival of B-cells. By inhibiting this enzyme, idelalisib D5 disrupts the signaling pathways that promote cell growth and survival, leading to the death of cancer cells.
Chemically, idelalisib D5 has a molecular formula of C22H15D5N6O3S and a molecular weight of 455.5 g/mol. It is a white to off-white crystalline powder that is sparingly soluble in water and slightly soluble in ethanol. The deuterium labeling of idelalisib D5 serves as a tracer to help researchers better understand the pharmacokinetics and metabolism of the drug in vivo.
Idelalisib D5 is typically administered orally in the form of tablets or capsules, and dosages may vary depending on the type of cancer being treated and the patient's individual health status. While idelalisib D5 has shown promising results in clinical trials, it is important to note that it can cause side effects such as diarrhea, fatigue, and nausea. Patients should always consult with their healthcare provider before beginning treatment with idelalisib D5.
